New test to help fight deadly melanoma

New test to help fight deadly melanoma
Metastatic melanoma tumour cells showing low levels of LC38 (green) and high G9a (red) in Nonresponder to immunotherapy. Credit: QIMR Berghofer Medical Research Institute

Researchers from QIMR Berghofer Medical Research Institute have developed a prototype test that can help identify if patients with deadly metastasised melanoma are likely to benefit from immunotherapy.

Details about the test and the study are being published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

The prototype test detects levels of the protein LC3B on cancer cells. High levels of LC3B are associated with better patient responses to a form of treatment known as checkpoint inhibitor immunotherapy.

Metastatic is a very aggressive disease and according to the Australian Institute of Health and Welfare, 1,375 Australians died from it in 2020.

Most patients undergo surgery and almost all patients with are now given immunotherapy as a standard frontline treatment.

Lead researcher Associate Professor Jason Lee, who heads QIMR Berghofer's Epigenetics and Disease group, said immunotherapies have remarkably improved treatment and for metastatic melanoma, but more than half of all patients do not respond.

"We need to treat these patients quickly and with the correct kinds of drugs to have any success," Associate Professor Lee said.

"Our study found patients with high levels of LC3B in their tumor cells had significantly longer survival due to better responses to immunotherapy treatment than those with lower levels. The study showed 95% of patients with high LC3B levels were alive after three years, compared to 60% of patients with low LC3B levels."

New test to help fight deadly melanoma
Credit: QIMR Berghofer Medical Research Institute

The researchers used tumor and collected from melanoma patients before and after treatment to get a better understanding of the role of the LC3B protein in metastatic melanoma and to develop the prototype test.

Ph.D. candidate in QIMR Berghofer's Epigenetics and Disease group, Greg Kelly, said they also identified that patients with metastatic melanoma had very high levels of the epigenetic enzyme G9a—which acts on LC3B protein.

"The enzyme G9a acts like a traffic jam, reducing the ability of cancer fighting immune cells to reach the tumor," Mr Kelly said.

"Building on the group's previous work, we explored how targeting the G9a enzyme could help in the fight against melanoma. Our showed inhibiting the G9a enzyme led to higher levels of LC3B proteins so the immune system could re-engage in the fight against melanoma both on its own, and in combination with immunotherapy."

Associate Professor Lee said the findings provided hope of new treatment options in the future.

"We are now also working to develop a drug that can effectively inhibit the G9a enzyme," Associate Professor Lee said.

"We believe blocking the activity of G9a enzymes will in turn raise the level of LC3B protein, making patients more responsive to immunotherapy and possibly even other treatments.

"We are actively working to develop a drug that can be used to treat patients, but this will take time."

Associate Professor Lee said the researchers plan to expand the study using a larger set of patient samples to test the robustness of the prototype test to predict resistance.

Explore further

Scientists identify new target for melanoma immunotherapy

More information: Greg Kelly et al. G9a inhibition enhances checkpoint inhibitor blockade response in melanoma, Clinical Cancer Research (2021). DOI: 10.1158/1078-0432.CCR-20-3463
Journal information: Clinical Cancer Research

Provided by QIMR Berghofer Medical Research Institute
Citation: New test to help fight deadly melanoma (2021, February 15) retrieved 11 April 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments